Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Wall Street's Best Hidden Stocks

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

When asked for the secret of his success, baseball player Wee Willie Keeler replied, "Hit 'em where they ain't." What worked for Willie at the plate applies equally well in investing. 

Seeking stocks that others ignore, shun, or simply forget gives individual investors like you an edge over the professionals. When Wall Street turns a blind eye, you have a chance to get in before these stocks get discovered -- or rediscovered -- and start taking off. 

Below, we'll check out companies with only a handful of analyst coverage, then pair our list with the opinions of the Motley Fool CAPS community. A stock that garners CAPS' top ratings but hasn't yet caught analysts' attention could be your next home run investment.


CAPS Rating (out of 5)

Wall St. Picks

Wall St. Bullish Sentiment

Est. EPS Growth Next Year

Antares Pharma (AMEX: AIS  ) **** 1 100% NC
CVR Partners (NYSE: UAN  ) ***** 0 N/A <1%

Sources: Yahoo! Finance; Motley Fool CAPS. NC = not calculable; N/A = not available.

Remember, without much analyst support, you'll have to do more scouting on your own to see whether these stocks deserve a spot on your portfolio's roster. Don't just buy or sell them based solely on their appearance here. 

Hiding in plain sight
The efficient-market theory got stood on its head last month when shares of Antares Pharma plummeted after BioSante Pharmaceuticals reported it had halted testing on its "female Viagra" LibiGel because the topical cream did no better than a placebo in raising the libido of women. Antares supplies BioSante with the gel needed to make the cream. The only problem is, BioSante represents just a tiny fraction of Antares sales; it derives most of its revenues from Teva Pharmaceutical (Nasdaq: TEVA  ) and privately held Ferring Pharmaceuticals, and it has partnerships in place with Pfizer and Jazz Pharmaceuticals (Nasdaq: JAZZ  ) , too. The problems at BioSante should have minimal if any impact on Antares' performance.

EMT suggests that the market has perfect knowledge and that stock prices reflect all available knowledge. Yet it's inefficiencies like the above that give investors a chance to achieve outsize gains. Shares of Antares have bounded 50% higher in the weeks after, as investors realized that BioSante wasn't going to be a bioshock to the system.

Losses are expected to improve for the year when Antares reports fourth-quarter results, and it's anticipated to turn profitable thereafter. CAPS member micro1943 expects its pipeline of drugs to secure it a stable future: "Excellent management, solid stable of products and positive earnings which will be coming within a few months."

Let us know in the comments section below or on the Antares Pharma CAPS page whether you think the market can be a messy, inefficient arena, then add it to your watchlist to be notified when the stock gains altitude.

Growth initiatives
Pure-play nitrogen producer CVR Partners ought to benefit from improving commodity prices, particularly for corn and wheat, both of which have seen strong price appreciation lately. After a torrid rate of growth early last year, grain prices crumbled, taking with them fertilizer producer PotashCorp (NYSE: POT  ) , which has lost a quarter of its value over the past six months (both CVR and PotashCorp have recorded double-digit gains in the last 30 days).

As demand for crop fertilizer expands, CVR, as one of the leading producers of fertilizers in the U.S., ought to do well. It produces about 2,000 tons of urea ammonium nitrate and about 1,200 tons of ammonia per day. With its healthy dividend, which currently yields 7.9%, investors will also do well while waiting for the fruits of its labors to blossom. That could be why all 72 CAPS All-Stars rating the nitrogen producer believe it will outperform the broad market averages.

Plant your own opinion on the CVR Partners CAPS page and add the stock to the Fool's free portfolio tracker to see whether it can grow to the sky.

Swing for the fences
If you're looking for other hidden stock opportunities to help you get one up on Wall Street, then grab a copy of this free report. In it, you'll find five stocks the Fool owns and you should too, including one top-notch technology stock. Just click here to get your copy today -- it's totally free.

Fool contributor Rich Duprey owns shares of Pfizer, but he holds no other position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Teva Pharmaceutical Industries. Motley Fool newsletter services have recommended buying shares of Pfizer and Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (13)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1765653, ~/Articles/ArticleHandler.aspx, 10/28/2016 6:55:31 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 9 hours ago Sponsored by:
DOW 18,169.68 -29.65 -0.16%
S&P 500 2,133.04 -6.39 -0.30%
NASD 5,215.97 -34.29 -0.65%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/27/2016 4:00 PM
ATRS $1.75 Up +0.02 +1.16%
Antares Pharma CAPS Rating: **
UAN $5.04 Up +0.29 +6.11%
CVR Partners CAPS Rating: ****
JAZZ $119.13 Up +1.57 +1.34%
Jazz Pharmaceutica… CAPS Rating: ****
POT $16.46 Down -0.32 -1.91%
PotashCorp CAPS Rating: ****
TEVA $43.15 Down -0.21 -0.48%
Teva Pharmaceutica… CAPS Rating: ****